Switch to:
Also traded in: Germany

Latest Guru Trades with NYSE:WAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:MTD, NYSE:RMD, TSE:7733, OCSE:COLO B, NAS:XRAY, NYSE:COO, XSWX:STMN, NAS:HOLX, TSE:4543, NYSE:STE, SZSE:002294, NYSE:WST, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD, TSE:7747, NYSE:HAE, MIL:AMP, OSTO:LIFCO B » details
Traded in other countries:WAZ.Germany,
Headquarter Location:USA
Waters Corp is an analytical instrument manufacturer. It designs, manufactures, sells and services liquid chromatography, ultra performance liquid chromatography & mass spectrometry instrument systems & support products.

Waters provides analytical instruments for pharmaceutical, biochemical, and industrial customers. Roughly half of sales are attributable to instruments, which include liquid chromatography and mass spectrometry platforms, as well as thermal analysis tools. Consumables and services account for the remainder of Waters' sales.

Ratios

vs
industry
vs
history
PE Ratio 32.06
WAT's PE Ratio is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. WAT: 32.06 )
Ranked among companies with meaningful PE Ratio only.
WAT' s PE Ratio Range Over the Past 10 Years
Min: 9.64  Med: 20.98 Max: 1038.76
Current: 32.06
9.64
1038.76
Forward PE Ratio 26.39
WAT's Forward PE Ratio is ranked higher than
50% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WAT: 26.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.06
WAT's PE Ratio without NRI is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. WAT: 32.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
WAT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.64  Med: 20.98 Max: 1038.76
Current: 32.06
9.64
1038.76
Price-to-Owner-Earnings 37.34
WAT's Price-to-Owner-Earnings is ranked higher than
54% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. WAT: 37.34 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.12  Med: 23.51 Max: 37.34
Current: 37.34
10.12
37.34
PB Ratio 11.85
WAT's PB Ratio is ranked lower than
65% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. WAT: 11.85 )
Ranked among companies with meaningful PB Ratio only.
WAT' s PB Ratio Range Over the Past 10 Years
Min: 4.38  Med: 5.69 Max: 11.85
Current: 11.85
4.38
11.85
PS Ratio 7.85
WAT's PS Ratio is ranked lower than
67% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. WAT: 7.85 )
Ranked among companies with meaningful PS Ratio only.
WAT' s PS Ratio Range Over the Past 10 Years
Min: 2.05  Med: 4.7 Max: 7.85
Current: 7.85
2.05
7.85
Price-to-Free-Cash-Flow 37.43
WAT's Price-to-Free-Cash-Flow is ranked higher than
55% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. WAT: 37.43 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.66  Med: 22.66 Max: 37.43
Current: 37.43
9.66
37.43
Price-to-Operating-Cash-Flow 31.45
WAT's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. WAT: 31.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.82  Med: 18.31 Max: 31.45
Current: 31.45
7.82
31.45
EV-to-EBIT 23.20
WAT's EV-to-EBIT is ranked higher than
58% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. WAT: 23.20 )
Ranked among companies with meaningful EV-to-EBIT only.
WAT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 16.6 Max: 24.5
Current: 23.2
8.4
24.5
EV-to-EBITDA 20.20
WAT's EV-to-EBITDA is ranked higher than
50% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. WAT: 20.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
WAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 14.3 Max: 21.3
Current: 20.2
7.2
21.3
EV-to-Revenue 7.01
WAT's EV-to-Revenue is ranked lower than
60% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. WAT: 7.01 )
Ranked among companies with meaningful EV-to-Revenue only.
WAT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 4.5 Max: 7.4
Current: 7.01
2.1
7.4
PEG Ratio 3.24
WAT's PEG Ratio is ranked lower than
99.99% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. WAT: 3.24 )
Ranked among companies with meaningful PEG Ratio only.
WAT' s PEG Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.76 Max: 114.91
Current: 3.24
0.59
114.91
Shiller PE Ratio 47.91
WAT's Shiller PE Ratio is ranked lower than
59% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. WAT: 47.91 )
Ranked among companies with meaningful Shiller PE Ratio only.
WAT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.73  Med: 30.07 Max: 47.9
Current: 47.91
16.73
47.9
Current Ratio 5.93
WAT's Current Ratio is ranked higher than
91% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. WAT: 5.93 )
Ranked among companies with meaningful Current Ratio only.
WAT' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 1.99 Max: 7.04
Current: 5.93
1.25
7.04
Quick Ratio 5.28
WAT's Quick Ratio is ranked higher than
92% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. WAT: 5.28 )
Ranked among companies with meaningful Quick Ratio only.
WAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.67 Max: 6.6
Current: 5.28
0.74
6.6
Days Inventory 108.46
WAT's Days Inventory is ranked higher than
65% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. WAT: 108.46 )
Ranked among companies with meaningful Days Inventory only.
WAT' s Days Inventory Range Over the Past 10 Years
Min: 102.7  Med: 107.8 Max: 110.42
Current: 108.46
102.7
110.42
Days Sales Outstanding 85.72
WAT's Days Sales Outstanding is ranked lower than
62% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. WAT: 85.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
WAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 72.38  Med: 81.25 Max: 85.72
Current: 85.72
72.38
85.72
Days Payable 25.07
WAT's Days Payable is ranked lower than
70% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. WAT: 25.07 )
Ranked among companies with meaningful Days Payable only.
WAT' s Days Payable Range Over the Past 10 Years
Min: 24.87  Med: 28.41 Max: 35.98
Current: 25.07
24.87
35.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.30
WAT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. WAT: 2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 2.4 Max: 6.3
Current: 2.3
-3.1
6.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 36.94
WAT's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. WAT: 36.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WAT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.43  Med: 14.78 Max: 104.38
Current: 36.94
8.43
104.38
Price-to-Tangible-Book 19.26
WAT's Price-to-Tangible-Book is ranked lower than
65% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. WAT: 19.26 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WAT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.17  Med: 12.06 Max: 46.51
Current: 19.26
6.17
46.51
Price-to-Intrinsic-Value-Projected-FCF 2.48
WAT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. WAT: 2.48 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WAT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.89  Med: 1.66 Max: 10.23
Current: 2.48
0.89
10.23
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.00
WAT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. WAT: 3.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WAT' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.51  Med: 1.3 Max: 85.86
Current: 3
0.51
85.86
Price-to-Median-PS-Value 1.68
WAT's Price-to-Median-PS-Value is ranked lower than
62% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. WAT: 1.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 0.95 Max: 3.06
Current: 1.68
0.27
3.06
Price-to-Peter-Lynch-Fair-Value 3.02
WAT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. WAT: 3.02 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WAT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.78 Max: 101.68
Current: 3.02
0.68
101.68
Price-to-Graham-Number 5.24
WAT's Price-to-Graham-Number is ranked lower than
99.99% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. WAT: 5.24 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WAT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.35  Med: 3.39 Max: 17.89
Current: 5.24
2.35
17.89
Earnings Yield (Greenblatt) % 4.31
WAT's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. WAT: 4.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.1  Med: 6 Max: 11.9
Current: 4.31
4.1
11.9
Forward Rate of Return (Yacktman) % 13.13
WAT's Forward Rate of Return (Yacktman) % is ranked lower than
51% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. WAT: 13.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WAT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.1  Med: 14.5 Max: 24
Current: 13.13
9.1
24

More Statistics

Revenue (TTM) (Mil) $2,419.93
EPS (TTM) $ 7.65
Beta1.29
Volatility26.00%
52-Week Range $167.94 - 246.43
Shares Outstanding (Mil)71.51

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 2,507 2,638 2,780
EBIT (Mil $) 774 833 889
EBITDA (Mil $) 861 913 978
EPS ($) 9.15 10.55 11.87
EPS without NRI ($) 9.15 10.55 11.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.81%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK